Celltrion Approved to Start China Trials of Remicade Biosimilar

Celltrion, a South Korean biosimilar company, received CFDA approval to begin clinical trials of Remsima, a biosimilar to Johnson & Johnson’s arthritis treatment Remicade. Remsima has the distinction of being the first foreign antibody biosimilar approved for an efficacy/safety test in China, according to Celltrion, which filed for trial approval in January 2014. That's a long time to wait, even for China. Rensima is already marketed in Europe and the US. More details.... Stock Symbols: (KOSDAQ: 068270) (NYSE: JNJ) Share this with colleagues: // //